Research programme: Parkinson's disease therapeutics - Integrative Research LaboratoriesAlternative Names: IRL 448; IRL 555
Latest Information Update: 01 Mar 2016
At a glance
- Originator Integrative Research Laboratories
- Class Small molecules
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Parkinson's disease
Most Recent Events
- 01 Mar 2016 Preclinical trials in Parkinson's disease in Sweden (unspecified route) before March 2016